Drug Profile
Clostridium difficile vaccine - Sanofi
Alternative Names: ACAM Cdiff; ACAM-CDIFF; CdVax; Clostridium difficile toxoid vaccine - sanofi pasteurLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Acambis
- Developer Sanofi Pasteur
- Class Bacterial vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Clostridium difficile infections
Most Recent Events
- 01 Dec 2017 Sanofi Pasteur terminates a phase III trial for Clostridium difficile infections (prevention) in USA, Canada, Australia, Brazil, Chile, Colombia, Finland, France, Germany, South Korea, Mexico, Peru, Puerto Rico, Singapore, Sweden, Taiwan, United Kingdom, Spain, Poland, Denmark, Czech Republic, Cost Rica, Dominican Republic, Guatemala, Japan, South Korea, Panama, Peru and Philippines based on the interim analysis by the Independent Data Monitoring Committee indicating a low probability for achieving primary endpoints (IM) (NCT01887912)
- 01 Dec 2017 Discontinued - Phase-II for Clostridium difficile infections in USA, United Kingdom (IM)
- 01 Dec 2017 Discontinued - Phase-III for Clostridium difficile infections (Prevention) in USA, Canada, Australia, Brazil, Brazil, Chile, Chile, Colombia, Finland, France, Germany, South Korea, Mexico, Peru, Puerto Rico, Puerto Rico, Singapore, Sweden, Taiwan, United Kingdom, Spain, Poland, Denmark, Czech Republic, Costa Rica, Guatemala, Dominican Republic, Guatemala, Panama, Philippines, Japan (IM)